Innovative Leukemia and Lymphoma Therapy PDF Download

Author: Gertjian J. L. Kaspers
Publisher: CRC Press
ISBN: 042952465X
Category : Medical
Languages : en
Pages : 622

View

Book Description
Innovative Leukemia and Lymphoma Therapy provides a complete and up-to-date overview of the exciting new treatment modalities in leukemia and lymphoma that are being introduced in the clinic today. Written by international experts in the field, this volume examines clinical studies on topics such as:tyrosine kinase inhibitors, histon deacetyla

Author: Jasmine Zain
Publisher: Springer
ISBN: 3319268279
Category : Medical
Languages : en
Pages : 258

View

Book Description
This book will provide an overview of how to manage patients with lymphoma in the format of a series of engaging case studies. Lymphomas are cancers that originate in the lymphatic system. There are two main types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. These lymphomas comprise various subtypes with prognosis and treatment depending on the stage and type of the cancer. Lymphoma is a major global health problem; non-Hodgkin lymphoma in particular is the tenth most common type of cancer worldwide. In response to this there have been a number of significant advances in the available treatment options for lymphoma with new breakthrough drugs being approved or registered for approval. In light of this, this case study book will be an extremely timely guide for all hematologists, oncologists, and healthcare professionals wishing to keep up-to-date with these recent developments. The format of this book is also particularly appealing as it offer readers a practical approach to the clinical management of patients with these conditions as suggested by leading physicians from the City of Hope National Medical Center in California, USA in an era of vast therapeutic development.

Author: David A. Scheinberg
Publisher: Elsevier
ISBN: 0080490409
Category : Medical
Languages : en
Pages : 417

View

Book Description
New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology. Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals, inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers. The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future. * Provides an up-to-date, state of the art discussion of a rapidly changing field * Great breadth covering conventional chemotherapeutic agents, biologic agents such as antibodies, novel small molecule inhibitors and genetically engineered cells * Written by international experts in each of the fields

Author: Theodore F. Zipf
Publisher: Springer Science & Business Media
ISBN: 1592593186
Category : Medical
Languages : en
Pages : 355

View

Book Description
In Leukemia and Lymphoma: Detection of Minimal Residual Disease, hands-on experts describe and discuss the minimal residual disease (MRD) methods they have successfully pioneered for leukemias and lymphomas. They apply reverse transcription PCR (RT-PCR) to acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and acute promyelocytic leukemia (APL). Other PCR methods are used for Non-Hodgkin's Lymphoma and for the monitoring of follicular lymphoma. Additional chapters address the use of real-time quantitative PCR (RQ-PCR), the emergent method of choice, in patients with acute lymphoblastic leukemia (ALL), the evaluation of MRD techniques in clinical trials, and the application of flow cytometry techniques.

Author: Christopher Dittus
Publisher: Springer Nature
ISBN: 3030256103
Category : Medical
Languages : en
Pages : 253

View

Book Description
This comprehensive volume reviews the clinical presentation, diagnosis, and treatment approach to rare lymphomas. There is particular emphasis placed on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents, Novel Therapeutics for Rare Lymphomas covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas.

Author: Vaskar Saha
Publisher: Springer Science & Business Media
ISBN: 1441984593
Category : Medical
Languages : en
Pages : 349

View

Book Description
The majority of cancers present at a relatively advanced stage in which invasion within the primary organ is well established and metastases to lymph and distant organs are either clinically apparent or present at the microscopic level. However, it is increasingly recognized that the natural history of cancer formation is a long and complex path taking many years to develop to a clinically apparent stage in most cases. Furthermore, for most solid tumours there is a pre-invasive or intraepithelial stage of disease. This affords the opportunity for early detection and prevention of invasive disease and hence a cure. However, with this advancing knowledge comes a whole plethora of questions which will be explored in this monograph. Firstly, we need to understand the global burden of pre-invasive disease and what the public health implications might be for wide-scale screening programmes. In the western world we already have experience of screening for cervical, breast, prostate and more recently colon cancer. As well as their potential benefits these programmes have financial and psychosocial implications which need to be carefully weighed. This is especially true since many pre-invasive lesions will not progress to cancer in a individual’s lifetime. In addition, there are questions concerning whether screening reduces the cancer burden or in fact distorts the survival figures through lead-time bias. Secondly, at the level of epidemiology and molecular pathogenesis there are important questions regarding the aetiology of pre-invasive lesions; an understanding of which might lead to possible chemopreventive strategies. For example, it would be helpful to know the extent to which the likelihood of developing a pre-invasive lesion is influenced by lifestyle or genetic factors and how these factors influence the risk of progression to invasive disease. At the molecular level we need to understand the pathways and molecular mechanisms, both genetic and epigenetic, by which cells achieve the capacity to invade. Thirdly, in order make clinical progress we need biomarkers to identify and risk stratify individuals with pre-invasive lesions. These biomarkers might be applied to the serum as in Prostate Specific Antigen in prostate cancer or be applied to tissue samples, such as oestrogen receptor status in breast cancer. In order to utilize biomarkers in the context of a screening programme there are issue around the invasiveness of the test as well as its positive and negative predictive value. With advances in molecular imaging there is now the exciting possibility of incorporating a molecular tag to a non-invasive imaging modality. Fourthly, in order to justify screening early detection must be coupled to a treatment strategy. If the chemopreventive agent is very well tolerated, then as well as targeting high risk groups, one might consider treatment at the population level. Aspirin is one such drug which has been extensively assessed in the context of colon cancer chemoprevention trials. Trials of aspirin chemoprevention are now being applied to other cancers such as oesophageal adenocarcinoma and since many individuals take aspirin for .chemoprevention of cardiovascular disease the cancer incidence can be ascertained in these populations. In order to understand the more general issues raised from the discussions above it is useful to consider disease specific examples. Our understanding of pre-invasive disease varies according to the organ site and there are lessons to be learned from these experiences. For example, there is now the prospect of a vaccine for cervical cancer with important questions about how this might be applied to the high incidence areas of the developing world. On the other hand, ductal carcinoma in situ is currently treated by mastectomy which is more radical than the treatment received by many women with invasive disease. Oesophageal adenocarcinoma, which is my own area of expertise is interesting because of the rapid rise in incidence in the western world and the clinically accessible pre-invasive lesion called Barrett’s oesophagus. However, most cases of Barrett’s oesophagus remain undiagnosed and it is not yet clear how to effectively diagnose, monitor and treat this condition without recourse to mass endoscopy with substantial cost implications. In conclusion, in an era in which preventive medicine is a major concern for consumers, health-policy makers and politicians pre-invasive disease is likely to become a major part of cancer medicine.

Author: Steven T. Rosen
Publisher: Springer Science & Business Media
ISBN: 1461530768
Category : Medical
Languages : en
Pages : 293

View

Book Description
The hybridoma technique for producing monoclonal antibodies, developed by Drs. Kohler and Millstein in 1975, revolutionized the field of tumor immunology. It is now clear that there are antigens associated with or restricted to human neoplasms that have biologic significance. Monoclonal antibodies have already been demonstrated to have great immunodiagnostic value and it is anticipated that they will become a component of our therapeutic armamentarium. Most investigators in the field, however, feel that the true potential of monoclonal antibodies in cancer therapy remains to be determined. Clearly the most encouraging results have been witnessed in the treatment of hematologic malignancies. This volume of CANCER TREATMENT AND RESEARCH explores the current state of the art of immunoconjugate therapy of hematologic malignancies. Immunoconjugate Therapy of Hematologic Malignancies provides an update of a rapidly advancing field. The preliminary experience of a number of investigators suggests a role for targeted therapy in the treatment of hematologic malignancies. At the present time, immunoconjugates have, in most instances, been reserved for patients with advanced refractory disease. However, it is anticipated in the future that these reagents will be utilized as a complement to traditional therapy or as post-remission consolidation in patients with minimal residual disease. The obstacles have been defined; solutions will require further research and creative imagination.

Author: Michael G. Kharas
Publisher:
ISBN: 9781621821427
Category : Leukemia
Languages : en
Pages : 300

View

Book Description
Leukemia and lymphoma are cancers that affect cells of the blood. This book examines the genetic and epigenetic changes in blood cells that lead to these conditions and current treatment strategies. Topics covered in this essential volume include: - Cancer Stem Cells - Pediatric Leukemias and Lymphomas - Mouse Models of Myeloid Malignancies - Non-Hodgkin Lymphomas - Immunotherapy - The Future of New Treatment Paradigms

Author: Lidia Gil
Publisher:
ISBN: 9781022900004
Category : Medical
Languages : en
Pages : 0

View

Book Description
Exploring New Frontiers in Non-Hodgkin Lymphoma: Insights from Innovative Research offers a meticulously curated collection of scientific journal articles that delve into the latest advancements and challenges in the field of Non-Hodgkin Lymphoma (NHL) research. This anthology encompasses a broad range of topics, including the efficacy of Bendamustine-based therapies, the revolutionary use of CAR T-cell treatments highlighted by FDA-approved Yescarta(R), and the burgeoning field of immune checkpoint inhibitors. The comprehensive examination includes discussion of mechanisms of drug resistance, novel therapeutic strategies in resource-limited settings, and the potential of innovative agents like FNC. Additionally, the intersection of HIV and NHL, radiological advancements in guiding therapies, the effects of light therapy on cancer-related fatigue, and safety concerns such as HBV reactivation are thoroughly explored. This collection not only provides profound insights into NHL treatment and research but also underscores the complex, multidisciplinary approach necessary to combat this multifaceted disease. Ideal for clinicians, researchers, and patient advocates, this volume is poised to enhance understanding and inspire further scientific inquiry in the relentless fight against non-Hodgkin lymphoma. Quality Research Publishing is dedicated to making knowledge more accessible to the general public by curating a topical compilation of the latest research on various subjects and providing plain language summaries. Each of the articles in this book is available individually and digitally without cost. However, we believe it is important for the contextualizing and sharing of educational and scientific work to curate this research in a way that is understandable and helpful to the average person seeking deeper knowledge of a particular subject. The research articles compiled for this book were published under a permissive Creative Commons license, are in the public domain, or have no copyright restrictions, permitting their use in this book. If you have questions about the licensing of any article, please visit qualityresearchpublishing.com.

Author: Aamir Ahmad
Publisher:
ISBN: 9781022905092
Category : Medical
Languages : en
Pages : 0

View

Book Description
Illuminating Pathways: Advances in Leukemia Treatment and Therapy is an essential compendium of pivotal scientific journal articles that delve into the dynamic and ever-evolving field of leukemia research. With a foreword that underscores the transformative impact of recent therapies, this collection captures the forefront of scientific discoveries and clinical innovations in leukemia treatment. From CAR-T cell therapy and targeted approaches in pediatric acute lymphoblastic leukemia (ALL), to the challenges of adverse events and therapy-induced complications, each article offers profound insights and detailed analyses. The compilation features groundbreaking research on mechanisms and implications of novel treatments, including the efficacy of anti-CD19 CAR-T therapy in battling B-Cell malignancies and the promising role of nilotinib in combating drug-resistant leukemia. Additionally, case studies of acute pancreatitis and diabetic ketoacidosis following L-asparaginase and prednisone therapy highlight the critical balance between efficacy and safety in treatment protocols. Targeting genetic abnormalities with precision medicine, understanding the adverse events of such therapies, and exploring innovative combinational approaches, this book serves as a beacon for healthcare professionals, researchers, and medical students keen on the latest advancements in leukemia therapy. A compelling narrative of hope, resilience, and relentless pursuit, this work is an invitation to grasp the future of leukemia treatments with both compassion and scientific precision. Quality Research Publishing is dedicated to making knowledge more accessible to the general public by curating a topical compilation of the latest research on various subjects and providing plain language summaries. Each of the articles in this book is available individually and digitally without cost. However, we believe it is important for the contextualizing and sharing of educational and scientific work to curate this research in a way that is understandable and helpful to the average person seeking deeper knowledge of a particular subject. The research articles compiled for this book were published under a permissive Creative Commons license, are in the public domain, or have no copyright restrictions, permitting their use in this book. If you have questions about the licensing of any article, please visit qualityresearchpublishing.com.